首页> 美国卫生研究院文献>PLoS Clinical Trials >A Randomised Trial of an Eight-Week Once Weekly Primaquine Regimen to Prevent Relapse of Plasmodium vivax in Northwest Frontier Province Pakistan
【2h】

A Randomised Trial of an Eight-Week Once Weekly Primaquine Regimen to Prevent Relapse of Plasmodium vivax in Northwest Frontier Province Pakistan

机译:巴基斯坦西北边境省八周一次每周一次的伯氨喹治疗以预防间日疟原虫复发的随机试验。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundVivax malaria remains a major cause of morbidity in the subtropics. To undermine the stability of the disease, drugs are required that prevent relapse and provide reservoir reduction. A 14-day course of primaquine (PQ) is effective but cannot safely be used in routine practice because of its interaction with glucose-6-phosphate dehydrogenase (G6PD) deficiency for which testing is seldom available. Safe and effective use of PQ without the need for G6PD testing would be ideal. The efficacy and safety of an 8-week, once weekly PQ regimen was compared with current standard treatment (chloroquine alone) and a 14-day PQ regimen.
机译:背景Vivax疟疾仍然是亚热带地区发病的主要原因。为了破坏疾病的稳定性,需要药物以防止复发并减少储库。有效期为14天的伯氨喹(PQ)有效,但由于其与葡萄糖-6-磷酸脱氢酶(G6PD)缺乏症的相互作用而很少进行测试,因此不能安全地用于常规实践。无需进行G6PD测试就可以安全有效地使用PQ。将每周一次8周,每周一次的PQ方案与当前标准治疗(仅氯喹)和14天PQ方案的疗效和安全性进行比较。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号